Treatment of Progressive Multifocal Leukoencephalopathy with Third-Party Allogeneic BK Virus T Cells

Cliques: 19
ID: 319667
2026
PDF Gratuito
Metricas de Qualidade e Desempenho do Artigo
Qualidade Geral
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
Avaliacao de Qualidade por IA
Nao analisado
Readership in this journal
Steady

Ranked #478 of 635 articles by views in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 635 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Resumo
Abstract Background Progressive multifocal leukoencephalopathy (PML) is a fatal demyelinating disease caused by JC polyomavirus (JCV) that affects immunosuppressed individuals and has no approved therapy. Here we evaluate the safety and efficacy of third-party, off-the-shelf, partially HLA-matched BK virus-specific T cells (BK-VST) in patients with PML. Methods We conducted a single-center phase 2 study where 37 patients received most closely HLA-matched BK-VST at 2.0 x 105 T cells/kg, with additional infusions permitted for subjects who did not achieve a complete response. Twenty-three patients had an underlying diagnosis of hematologic malignancy. Each patient received a median of 2 doses (range, 1-12; IQR 2). Overall response (OR) was defined as virologic clearance with neurologic stabilization or improvement. Results During 12 months of follow-up, 21 patients (56.8%) achieved an OR, including 16 (43.2%) with a complete response. Responses were rapid (median 23 days) and durable, with no loss of response observed despite limited HLA matching. The 1-year overall survival was 61.1% (95% CI, 41.9-77.4). Patients achieving an OR after the first infusion had markedly improved 1-year survival compared with non-responders (93.3% vs 0%; p<0.001). Higher donor IL-2 and IFN-γ-producing T-cell frequencies and greater HLA matching correlated with clinical benefit. Conclusions These data demonstrate that third-party BK-VST infusions are safe and potentially effective, supporting a scalable immunotherapeutic approach for this otherwise fatal disease. (ClinicalTrials.gov NCT02479698).
Chave de Referencia
openalex_W7167405671 Use esta chave para citacao automatica no manuscrito ao usar SciMatic Gerenciador de Manuscritos ou Gerenciador de Teses
Autores Amanda Olson, Ye Li, David Marin, Peter F. Thall, Roland L. Bassett, Melissa Barnett, Rafet Başar, Pinaki P Banerjee, T Anne Kleiman, Merry Chen, Jennie Rexer, Max Wintermark, Jeanie Choi, Kim O. Learned, Indreshpal Kaur, Melihate Sylejmani, Glorette Abueg, Roy F. Chemaly, Victor E. Mulanovich, Rejeena Shrestha, Nadima Uprety, Karla Castro, May Daher, Isabel M. Galvan, Dominique Washington, Richard E Champlin, Elizabeth J. Shpall, Katayoun Rezvani
Are you one of these authors? Claim your profile
Periodico Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Ano 2026
DOI
10.1093/cid/ciag404
URL
https://doi.org/10.1093/cid/ciag404
Palavras-chave Palavras-chave nao encontradas

Citacoes

Nenhuma citacao encontrada. Para adicionar uma citacao, entre em contato com o administrador em info@scimatic.org

Comentarios

Nenhum comentario ainda. Seja o primeiro a comentar neste artigo.